Evidence map›Paper›PMID 42741788›Full record

ArticleBrain communications2026

Short-term heart rate variability is preserved in Parkinson's disease under atomoxetine.

Isabella F Orlando, Frank H Hezemans, Kamen A Tsvetanov, Rong Ye, Catarina Rua, Ralf Regenthal, Roger A Barker, Caroline H Williams-Gray, Luca Passamonti, Trevor W Robbins and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Isabella F OrlandoSchool of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney 2050, New South Wales, Australia.ORCID https://orcid.org/0009-0001-4515-3479
Frank H HezemansMRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge CB2 7EF, UK.
Kamen A TsvetanovDepartment of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge CB2 0SZ, UK.
Rong YeDepartment of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge CB2 0SZ, UK.ORCID https://orcid.org/0000-0003-2529-7755
Catarina RuaDepartment of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge CB2 0SZ, UK.
Ralf RegenthalDivision of Clinical Pharmacology, Rudolf-Boehm-Institute for Pharmacology and Toxicology, University of Leipzig, Leipzig 69978, Germany.
Roger A BarkerDepartment of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge CB2 0SZ, UK.
Caroline H Williams-GrayJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0SZ, UK.
Luca PassamontiDepartment of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge CB2 0SZ, UK.ORCID https://orcid.org/0000-0002-7937-0615
Trevor W RobbinsDepartment of Psychology, University of Cambridge, Cambridge CB2 3EA, UK.ORCID https://orcid.org/0000-0003-0642-5977
James B RoweMRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge CB2 7EF, UK.
Claire O'CallaghanSchool of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney 2050, New South Wales, Australia.ORCID https://orcid.org/0000-0001-5698-6364

Funding

Wellcome Trust
6 · The paper itself

Abstract

Repurposed noradrenergic drugs have been proposed to treat neuropsychiatric symptoms in Parkinson's disease and related conditions. While there is evidence that these drugs can be beneficial for cognition in selected patients, questions remain about their cardiovascular effects. Here, we tested whether heart rate variability (HRV) is altered in people with Parkinson's disease, following a single-dose challenge with the noradrenaline reuptake inhibitor atomoxetine (40 mg, oral). Consistent with previous work, our cohort of people with idiopathic Parkinson's disease (

Indexed as

atomoxetineheart rate variabilitylocus coeruleusnoradrenalineParkinson’s disease

Identifiers

PMID42741788
PMCPMC13574504

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.